Full text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Antimicrobial resistance is a major global health concern and one of the gravest challenges to humanity today. Antibiotic resistance has been acquired by certain bacterial strains. As a result, new antibacterial drugs are urgently required to combat resistant microorganisms. Species of Trichoderma are known to produce a wide range of enzymes and secondary metabolites that can be exploited for the synthesis of nanoparticles. In the present study, Trichoderma asperellum was isolated from rhizosphere soil and used for the biosynthesis of ZnO NPs. To examine the antibacterial activity of ZnO NPs against human pathogens, Escherichia coli and Staphylococcus aureus were used. The obtained antibacterial results show that the biosynthesized ZnO NPs were efficient antibacterial agents against the pathogens E. coli and S. aureus, with an inhibition zone of 3–9 mm. The ZnO NPs were also effective in the prevention of S. aureus biofilm formation and adherence. The current work shows that the MIC dosages of ZnO NPs (25, 50, and 75 μg/mL) have effective antibacterial activity and antibiofilm action against S. aureus. As a result, ZnO NPs can be used as a part of combination therapy for drug-resistant S. aureus infections, where biofilm development is critical for disease progression.

Details

Title
Trichoderma-Mediated ZnO Nanoparticles and Their Antibiofilm and Antibacterial Activities
Author
Balagangadharaswamy, Shobha 1 ; Shivaram, Ashwini Bagepalli 2 ; Ghazwani Mohammed 3   VIAFID ORCID Logo  ; Umme, Hani 3   VIAFID ORCID Logo  ; Banan, Atwah 4 ; Alhumaidi, Maryam S 5 ; Basavaraju Sumanth 1   VIAFID ORCID Logo  ; Chowdappa Srinivas 1 ; Tekupalli, Ravikiran 1   VIAFID ORCID Logo  ; Wahab Shadma 6   VIAFID ORCID Logo  ; Ahmad, Wasim 7   VIAFID ORCID Logo  ; Ramachandrappa, Lakshmeesha Thimappa 1 ; Ansari, Mohammad Azam 8   VIAFID ORCID Logo 

 Department of Microbiology and Biotechnology, Bangalore University, Jnana Bharathi Campus, Bengaluru 560056, India; [email protected] (B.S.); [email protected] (S.B.); [email protected] (S.C.); [email protected] (T.R.) 
 Department of Microbiology, Sri Siddhartha Medical College, Tumkur 572107, India; [email protected] 
 Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia; [email protected] (M.G.); [email protected] (U.H.) 
 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24382, Saudi Arabia; [email protected] 
 Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia; [email protected] 
 Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia; [email protected] 
 Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam 34222, Saudi Arabia; [email protected] 
 Department of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia 
First page
133
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
2309608X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2779574842
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.